Lisata subsidiary Marea's MAR001 meets primary endpoint in Phase 2b triglyceride trial
LSTA•Marea Therapeutics, a Lisata Therapeutics subsidiary, met all objectives in Part A of its Phase 2b TYDAL-TIMI 78 trial of MAR001. Placebo-adjusted triglyceride reductions were 39.1% to 45.5% at Week 12 and were sustained through Week 24.
1. Trial results
In Part A of the Phase 2b TYDAL-TIMI 78 trial, MAR001 produced placebo-adjusted triglyceride reductions of 39.1% to 45.5% across three doses at Week 12 (p<0.001), sustained through Week 24. Participants with baseline triglycerides of at least 500 mg/dL achieved reductions from baseline of up to 72.2%.
2. Safety and next steps
Through 24 weeks, adverse events occurred in 69.5% of MAR001 recipients and 77.6% of placebo recipients, with no worsening of HbA1c. Part B is enrolling approximately 100 participants with severe hypertriglyceridemia; Marea is developing longer-acting MAR005 as its planned Phase 3 candidate.
